Why Halozyme Therapeutics Inc. Shares Surged

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Halozyme Therapeutics , a biopharmaceutical company focused on the development of human enzymes, gained as much as 24% after reporting its third-quarter earnings results.

So what: For the quarter, Halozyme reported a tripling in its revenue from the prior year to $16 million as its net loss shrank modestly to $19.3 million, or an adjusted EPS loss of $0.17, from $20 million in the year-ago period. By comparison, Wall Street had been expecting Halozyme to report just $14.6 million in revenue (a decisive beat), but also expected a narrower loss of just $0.15 per share. Halozyme's revenue soared on the heels of the European launch of Herceptin SC and HyQvia. The launches of these two drugs also resulted in milestone payments of $10 million and $4 million, respectively, which will be recognized in upcoming quarters.

Now what: The good news here is that Herceptin SC, a subcutaneous version of cancer drug Herceptin that can be delivered rapidly compared to the IV version, has a shot at being a real revenue growth driver for Halozyme moving forward. The downside is that it's probably going to be a few years before Halozyme is profitable based on product sales alone, which makes its current $1.5 billion market valuation potentially frothy. This is certainly a name that biotech-savvy investors would be smart to have on their watchlist, but at its current price I'm perfectly happy remaining on the sidelines.

Another stock growing by leaps and bounds
There's no denying that Halozyme's growth rate is impressive -- but so is the growth rate for this incredible tech stock, which is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!

The article Why Halozyme Therapeutics Inc. Shares Surged originally appeared on Fool.com.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story